Andrew I. Aronsohn, MD; Stacey B. Trooskin, MD, PhD, MPH
Jointly provided by Purdue University College of Pharmacy and Integritas Communications.
This activity is supported by independent educational grants from Gilead Sciences, Inc., and AbbVie, Inc.
Andrew I. Aronsohn, MD
Co-Principal Investigator, HepCCATT
Associate Professor of Medicine
Faculty, MacLean Center for Clinical Medical Ethics
Program Director, Transplant Hepatology Fellowship
University of Chicago Medicine
Stacey B. Trooskin, MD, PhD, MPH
Chief Medical Officer
Director of Viral Hepatitis Programs
Jonathan Lax Treatment Center
This educational activity is intended for hepatologists, gastroenterologists, infectious disease specialists, primary care providers, and other clinicians who are currently or new to treating HCV.
In this activity, expert faculty will present the epidemiologic imperative for HCV treatment as prevention within populations of people who inject drugs (PWID). Potential barriers to treatment of HCV-positive PWID, including outdated clinical assumptions regarding treatment eligibility and prescribing limitations, will be discussed. Backed by simplified treatment guidelines and clinical evidence for success in curing HCV in PWID, faculty will share real-world strategies for optimized treatment through integration of harm-reduction principles and practices across the HCV care continuum.
Upon completion of the educational activity,participants should be able to:
- Discuss national and local epidemiologic data on HCV-positive PWID
- Describe the feasibility, efficacy, and population benefits of treating HCV-infected PWID
- Prescribe DAA-drug regimens for the treatment of HCV-infected PWID
- Apply harm-reduction principles and practices across the HCV-care continuum
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Integritas Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Purdue University College of Pharmacy designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflict of Interest
All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
All additional planning committee members, staff, and reviewers of Integritas Communications and Purdue University College of Pharmacy have no relationships to disclose.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Andrew I. Aronsohn, MD: Nothing to disclose
Stacey B. Trooskin, MD, PhD, MPH: Grants/Research Support/Advisory Board: Gilead Sciences, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Purdue University College of Pharmacy and Integritas Communications do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to receive CME credits, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score at least 70% on the posttest. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
For information about the accreditation of this program, please contact Dawn Sinclair at The Purdue University College of Pharmacy at email@example.com or 765-494-5457. For questions regarding pharmacy CE credit and reports please contact: firstname.lastname@example.org.
Fee Information and Refund/Cancellation Policy
There is no fee for this educational activity.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 0.75
credit type CME
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV